PMID- 31468535
OWN - NLM
STAT- Publisher
LR  - 20190830
IS  - 1096-9098 (Electronic)
IS  - 0022-4790 (Linking)
DP  - 2019 Aug 29
TI  - S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC
      stage III melanoma patients.
LID - 10.1002/jso.25682 [doi]
AB  - BACKGROUND AND OBJECTIVES: This current study assessed the value of S-100B
      measurement to guide fluorodeoxyglucose (FDG) positron emission
      tomography/computed tomography (PET/CT) scanning for detecting recurrent disease 
      in stage III melanoma patients. METHODS: This study included 100 stage III
      melanoma patients in follow-up after curative lymph node dissection. Follow-up
      visits included physical examination and S-100B monitoring. FDG PET/CT scanning
      was indicated by clinical symptoms and/or elevated S-100B. RESULTS: Of 100
      patients, 13 (13%) had elevated S-100B without clinical symptoms, of whom 7 (54%)
      showed disease evidence upon FDG PET/CT scanning. Twenty-six patients (26%) had
      clinical symptoms with normal S-100B and FDG PET/CT revealed metastasis in 20
      (77%). Three patients had clinical symptoms and elevated S-100B, and FDG PET/CT
      revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed
      metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated
      S-100B prompted early detection of asymptomatic disease; 10% of all asymptomatic 
      patients in follow-up, 23% of all patients with recurrent disease. CONCLUSION:
      S-100B cannot exclude recurrent disease during follow-up of stage III melanoma.
      However, adding S-100B measurement to standard clinical assessment can guide FDG 
      PET/CT scanning for detecting recurrent melanoma.
CI  - (c) 2019 The Authors. Journal of Surgical Oncology published by Wiley
      Periodicals, Inc.
FAU - Deckers, Eric A
AU  - Deckers EA
AUID- ORCID: http://orcid.org/0000-0001-6206-207X
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - Wevers, Kevin P
AU  - Wevers KP
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - Muller Kobold, Anneke C
AU  - Muller Kobold AC
AD  - Department of Laboratory Medicine, University Medical Center Groningen,
      University of Groningen, Groningen, The Netherlands.
FAU - Damude, Samantha
AU  - Damude S
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - Vrielink, Otis M
AU  - Vrielink OM
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - van Ginkel, Robert J
AU  - van Ginkel RJ
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - Been, Lukas B
AU  - Been LB
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - van Leeuwen, Barbara L
AU  - van Leeuwen BL
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - Hoekstra, Harald J
AU  - Hoekstra HJ
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
FAU - Kruijff, Schelto
AU  - Kruijff S
AD  - Department of Surgical Oncology, University Medical Center Groningen, University 
      of Groningen, Groningen, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20190829
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
SB  - IM
OTO - NOTNLM
OT  - FDG PET/CT
OT  - S-100B
OT  - biomarker
OT  - follow-up
OT  - melanoma
OT  - recurrence
EDAT- 2019/08/31 06:00
MHDA- 2019/08/31 06:00
CRDT- 2019/08/31 06:00
PHST- 2019/04/19 00:00 [received]
PHST- 2019/08/05 00:00 [accepted]
PHST- 2019/08/31 06:00 [entrez]
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2019/08/31 06:00 [medline]
AID - 10.1002/jso.25682 [doi]
PST - aheadofprint
SO  - J Surg Oncol. 2019 Aug 29. doi: 10.1002/jso.25682.